新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较
DOI: 10.3971/j.issn.1000-8578.2019.18.1002
Keywords: An Update,Report on Six Cases of Invasive Bladder Cancer Treated with Natural Orifice Specimen Extraction Combined with Sigmoid Colon in situ Neo-bladder Surgery,Prognostic Effects of Different Courses of Neoadjuvant Chemotherapy on Stage N2-3 Locally Advanced Nasopharyngeal Carcinoma,Prognosis of Poorly-differentiated Gastric Neuroendocrine Neoplasm,Relationship of Integrinβ1 and CARMA-3 Protein Expressions with Recurrence of Bladder Cancer After Transurethral Resection of Bladder Tumor,Effectiveness of Neoadjuvant and Adjuvant Bladder Intracavitary Hyperthermic Perfusion Chemotherapy (BHPC) on High-risk Non-muscle-invasive Bladder Cancer Patients,Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients,Correlation of FoxO3 Gene with Clinicopathological Features and Prognosis of Bladder Cancer Patients,Clinical Efficacy of Gemcitabine plus S-1 on Refractory Nasopharyngeal Carcinoma Patients and Their Influence on Immune Function,Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer,Effect of Postoperative Chemotherapy on Prognosis of Postoperative Lymph Nodepositive Thoracic Esophageal Squamous Cell Carcinoma Patients,Mechanism About How Piceatannol Enhances Anti-tumor Effect of Cisplatin on Laryngeal Cancer Hep-2 Cells
Abstract:
摘要 目的 对接受新辅助和辅助化疗的膀胱癌患者临床疗效进行对比，为化疗时机的选择作初步探索。方法 回顾性研究湖北省肿瘤医院2009—2016年诊断为肌层浸润性膀胱癌并在全膀胱术前（新辅助）或术后（辅助）接受了GC方案化疗的患者。主要研究终点是无复发生存期（recurrencefree survival, RFS）。次要研究终点是临床完全缓解率（complete response, CR）。结果 共38例肌层浸润性膀胱癌患者纳入研究（22例新辅助+16例辅助）。在中位随访时间点时，新辅助和辅助化疗组的RFS相比较差异无统计学意义（69.6% vs.75.4%, P=0.223）。在中位随访时间点上接受新辅助化疗后病理完全缓解组（pT0）与非完全缓解组（non-pT0）的RFS分别为100%和50%（P=0.012），差异有统计学意义。两组患者在接受化疗治疗后出现3~4级严重血液学不良反应的人数比例相比较差异无统计学意义（P=0.36）。结论 接受新辅助或辅助化疗的肌层浸润性膀胱癌患者的RFS相比较差异无统计学意义，新辅助化疗后达到病理完全缓解的患者均未出现肿瘤复发，但尚需更多的研究来证实
Full-Text
